Skip to content

Measurements of central and peripheral refraction of the eye using a novel instrument, the EyeMapper.

A prospective, single-group, open-labelled study to measure central and peripheral refraction in healthy volunteers with a novel instrument, the EyeMapper.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12611000305921
Enrollment
40
Registered
2011-03-22
Start date
2011-03-15
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Peripheral refraction instrument - mode of operation. Participants will be recruited over a period of 5 months. Participants will be asked to attend the clinic for up to five visits. Each visit will take up to 1 hour. During these visits central and peripheral refraction measurements will be performed using up to three different instruments, the EyeMapper which is a novel peripheral refraction instrument, the Shin Nippon NVision K5001, a commercially available open view autorefractor and the C

Peripheral refraction instrument - mode of operation. Participants will be recruited over a period of 5 months. Participants will be asked to attend the clinic for up to five visits. Each visit will take up to 1 hour. During these visits central and peripheral refraction measurements will be performed using up to three different instruments, the EyeMapper which is a novel peripheral refraction instrument, the Shin Nippon NVision K5001, a commercially available open view autorefractor and the COAS, a commercially available aberrometer.

Sponsors

Brien Holden Vision Institute
Lead SponsorOther

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Participants enrolled in the trial must be able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent and must be at least 18 years old.

Exclusion criteria

Participants enrolled in the trial must not been currently enrolled in another clinical trial and must not have manifest strabismus or any anterior eye anomalies.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026